Resultado de búsqueda
21 de mar. de 2018 · John F. Seymour, Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia, Blood Advances, 8 , 8, (1992-2004), (2024)....
2022. Articles 1–20. Professor of Medicine, Director Dept of Haematology Peter MacCallum Cancer Centre & Royal Melbourne - Cited by 66,363 - Hematologic malignancies.
John Francis Seymour Jr. (born December 3, 1937) is an American retired politician who served as a United States senator from California from 1991 to 1992. A member of the Republican Party , he was appointed to continue Pete Wilson 's term but lost the special election to finish it to Democratic nominee and former San Francisco mayor ...
December 8th 2019. John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Centre, director of the integrated Haematology Department of the...
28 de mar. de 2024 · John F. Seymour. Blood (2024) 143 (13): 1218–1230. https://doi.org/10.1182/blood.2023022993. Article history. Share. Tools. Abstract. Targeted protein degradation (TPD) is a revolutionary approach to targeted therapy in hematological malignancies that potentially circumvents many constraints of existing small-molecule inhibitors.
9 de jun. de 2023 · John F. Seymour. First published: 09 June 2023. https://doi.org/10.1002/hon.3146. Sections. PDF. Tools. This section will review the assessment and approved and generally available treatment options for patients with relapsed CLL, including the context of Richter Transformation (the development of diffuse large B-cell lymphoma). 1.
24 de ago. de 2023 · Abstract. ELEVATE-RR demonstrated noninferior progression-free survival and lower incidence of key adverse events (AEs) with acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia. We further characterize AEs of acalabrutinib and ibrutinib via post hoc analysis.
